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BACKGROUND: Fluid and antimicrobial therapy are the 
essential parts of sepsis management. The type of fluid to 
resuscitate with is an unsettled issue in the treatment of severe 
sepsis and septic shock. The objective of this study was to evaluate 
the cost-effectiveness of albumin-based resuscitation over 
crystalloids. 
METHODS: A cost-effectiveness analysis was conducted by 
extracting data from a database of Sina Hospital, Islamic Republic 
of Iran. A decision tree was constructed by using Tree Age Pro 
2011. The patients were grouped based on the types of fluids used 
for resuscitation into crystalloid alone or crystalloid + albumin 
groups at the initial decision node. The patients were followed from 
the onset of severe sepsis and septic shock upto 28 days. The 
healthcare payers’ perspective was considered in constructing the 
model. The cost was measured in US dollars and the effectiveness 
was measured by life years gained. 
RESULTS: The addition of albumin during resuscitation of 
patients with severe sepsis and septic shock has an effectiveness 
gain of 0.09 life years and cost increment of 495.00 USD. The 
estimated ICER for this analysis was 5500.00 USD per life year 
gained. The probability that albumin is cost-effective at one GDP 
per capita is 49.5%. 
CONCLUSION: Albumin-based resuscitation is not cost-effective 
in Iran when a GDP per capita was considered for a life year gain. 
The cost-effectiveness was insensitive to the cost of standard care. 
We recomend the caustious use albumin as per the Surviving 
Sepsis Campaign guideline. 





Fluid resuscitation is the main part of severe sepsis and septic shock 
management (1,2). The ultimate goal of resuscitation is to enhance 
stroke volume and cardiac output (3).  The Surviving Sepsis 
Campaign recommends patients with hypotension or a lactate 
concentration >4 mmol/L, to receive a 30 ml/kg bolus of fluid 
within the first 3 hours, with additional fluid based on reassessment  
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 (4). However, considering the short-lived benefit 
of the hemodynamic fluid bolus, studies also 
recommended a conservative resuscitation strategy 
(5,6).    
Fluids used for volume replacement and 
resuscitation are generally classified into two 
groups: crystalloids and colloids (1,7). Crystalloids 
are composed of different electrolytes and water; 
can diffuse through the cell membranes. 
Nevertheless, colloids cannot diffuse through the 
cell membrane but create a positive oncotic 
pressure which leads to retention of fluid in the 
vascular compartment (8). The advantage of 
colloids over crystalloids is the volume sparing 
property (9). Albumin, normal saline and Ringer’s 
lactate are the common fluids used for resuscitation 
in the Islamic Republic of Iran (10).  
Large clinical trials came up with 
contradicting results on the mortality benefit of 
albumin over crystalloids. The SAFE study showed 
a 28-days mortality reduction benefit of albumin 
compared to normal saline (11). However, this 
effect was not confirmed for both 28-days mortality 
and 90-days mortality in ALBIOS study that 
compared the use of 20% albumin and crystalloid 
solution versus crystalloid solution alone (12). 
Although a few studies have been conducted on the 
cost-effectiveness of albumin-based resuscitation 
(13,14), the economic evaluation of fluid therapy in 
sepsis patients is not given important attention. In 
the US, albumin-based resuscitation had shown a 
0.21 life years gain with an incremental cost of 270 
US dollars when compared with crystalloids based 
resuscitation in severe sepsis and septic shock 
(13).The role of evaluating the effectiveness and 
cost of therapy is intuitively known by any policy 
maker and manager. Reasonable cost containment 
should be a target for each health sector particularly 
when the acquisition cost of the drug is expensive. 
Albumin is one of the drugs which can inflate 
healthcare expenditure if prescribed haphazardly. 
Therefore, we conducted this economic evaluation 
to evaluate the cost-effectiveness of albumin 







A retrospective database analysis was conducted 
for patients admitted with severe sepsis and septic 
shock in Sina Hospital from March 21, 2016 to 
September 22, 2017. The commonly used 
crystalloids, colloids, survival of patients under 
crystalloids, the average volume of fluids for fluid 
therapy and the cost of standard care for severe 
sepsis and septic shock patients were identified. 
This economic evaluation was done on crystalloids 
used for resuscitation of patients with severe sepsis 
and septic shock in Iran. The normal saline (0.9% 
NaCl), Ringer’s lactate, and 20% albumin were 
considered.The odds ratio for mortality was taken 
from a meta-analysis done on head-to-head 
comparison clinical trials to allow the calculation of 
probabilities for 28-days survival with the addition 
of albumin (15). 
Decision analysis model: A decision tree was 
constructed based on a hypothetical severe sepsis or 
septic shock patient population by using Tree Age 
Pro 2011 (Figure 1). The patients were grouped 
based on the types of fluids used for resuscitation 
into crystalloid alone or crystalloid + albumin 
groups at the initial decision node. The patients 
were followed from the onset of severe sepsis and 
septic shock upto 28 days. The healthcare payers’ 
perspective was considered in constructing the 
model. Each treatment arm has a chance node 
specifying 28-days mortality. Treatment-related 
adverse drug events were not considered. 
          Life years gained were calculated by the 
Declining Exponential Average Life Expectancy 
(DEALE) (16). A cost equivalent of one GDP per 
capita of the Islamic Republic of Iran was used 





Mortality: The variables used to populate the 
decision tree and the formulas used in the 
calculation are shown in Table 1 and Table 2. The 
odds ratio (OR) derived from the meta-analysis was 
converted to a probability of mortality with 
albumin and crystalloids using data for a 28-days 
mortality rate for patients with severe sepsis, and 
septic shock obtained from the retrospective 
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hospital database analysis using the formula given 
below.  
 
Where OR is the odds ratio 
The effectiveness of each treatment was calculated 
using theformula given below. 
 
 
Where LET is life expectancy with a given 
treatment, MR is the mortality rate in a given 
treatment and LEA is life expectancy for the 
general population at a given age 
Cost input: The standard cost of care for severe 
sepsis and septic shock was taken from a 
retrospective database analysis in Sina Hospital. 
The standard cost of care was expected to include 
all the costs except the cost of albumin. The cost of 
albumin was added to this cost to determine the 
cost of treatment with albumin. The price of 
albumin was taken from the Iranian Food and Drug 
Administration (IFDA) market report for 2016. The 
average volume of albumin required for the 
treatment was determined from the retrospective 
database analysis. All the costs were inflated to 
2017 costs using the Consumer Price Index (CPI) 
for health in 2016 and 2017 (17). Since all the costs 
were calculated for a time period of less than a 
year, no discount rate was used. 
 
Cost-effectiveness: Cost-effectiveness was 
evaluated using the incremental cost-effectiveness 
ratio (ICER). The ICER shows the incremental cost 
per additional life year gained from one treatment 
compared with another. 
Sensitivity analysis: The robustness of the model 
was checked by one-way sensitivity analysis, 
tornado diagram and probabilistic Sensitivity 
Analyses (SA). The probabilities of survival with 
the standard care and after the addition of albumin,  
the cost of standard care and cost of albumin were 
varied during the analysis.  
 




One hundred twenty-four severe sepsis and septic 
shock patients resuscitated only with crystalloids 
were identified from the retrospective database 
analysis. The average age of patients was 61 ± 2 
years and the mortality rate was 0.52 ± 0.05. The 
costs incurred during 2016 were adjusted to 2017 
before calculating the average cost.  A consumer 
price index for health from the central bank of Iran 
for Iranian years 1395 (100) and 1396 (108.9) was 
used for adjustment (17). The average cost of 
treatment was US $10,362.7 ±1017.6. A total of 
155 severe sepsis and septic shock patients 
resuscitated with crystalloids and albumin were 
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analyzed and the average volume of albumin was 
569 ±48ml. The volume was converted to bags of 
albumin (1 bag=20%,50ml albumin). Therefore, the 
average bags of albumin was 11.4± 1 bags. The 
average price of albumin taken from the IFDA 
market report for 2016 was 1,267,757 Iranian Rials. 
The average exchange rate for one American dollar 
during the data collection period was 31,820 IR 
(17). 
Base case analysis: The addition of albumin during 
resuscitation of patients with severe sepsis and 
septic shock had an effectiveness gain of 0.09 life 
years. However, the addition of albumin increased 
the cost of treatment by 495.00 USD compared 
with the standard treatment. Accordingly, the 
estimated ICER for this analysis was 5500.00 USD 
per life year gained (Table 3). Therefore, 
considering the GDP per capital of IRI (5219.2 
USD) (18), the use of albumin for resuscitation in 
severe sepsis and septic shock cannot be regarded 
as cost-effective. 
Sensitivity analysis: The one-way sensitivity 
analysis  showed that the cost-effectiveness was 
insensitive to the cost of standard care. However, it 
was sensitive for the changes in the cost of 
albumin, the probability of mortality with 
crystalloids only, mortality with the addition of 
albumin, life years gained with albumin, life years 
gained with crystalloids alone (Table 4). 
         The cost-effectiveness acceptability curve 
(Figure 2) showed that, relative to the assigned 
threshold of US $5219.2 per life year gained, 
albumin was cost-effective around 49.5% of the 
iteration. 
 
Table 1: Variables used to populate the decision analysis model 
 
Variable name 
(abbreviation in the model) 
Base case 
value  






Cost of albumin (C_albu) 495 412-578 Gamma  Calculated by taking the average price of 
albumin in IRI and the average volume of albumin 
used for resuscitation  
Cost of standard care 
(C_stand) 
10362.70 8348-12377 Gamma  Taken from a retrospective cohort study 
28-days mortality with 
crystalloids (P_stand) 
0.52 0.43-0.61 Beta  Taken from a retrospective cohort study 
28-days survival with 
crystalloids (Pa_stand) 
0.48 Not applied  Not applied  1-(P_stand) 
28-days mortality with 
crystalloids + albumin 
(P_albu) 
0.50 0.37-0.52 Beta  Calculated by using OR from meta-analysis and 
28-days mortality with crystalloids from the 
retrospective cohort 
28-days survival with 
crystalloids + albumin 
(Pa_albu) 
0.50 Not applied  Not applied  1-(P_albu) 
Life expectance of general 
population at 61 years 
(LEA)(19) 
14.5 Not applied Not applied  Calculated by subtracting the average age of 
severe sepsis or septic shock patients (61 years) 
from the average life expectancy of Iranians (75.5 
years)  
Life expectancy with 
crystalloids (L_stand) 
1.9 1.64-2.30 Not applied  Calculated based on DEALE by using life 
expectance of the general population and the 
mortality under the given treatment 
Life expectancy with 
crystalloids + albumin 
(L_albu) 
2.0 1.9-2.7 Not applied  Calculated based on DEALE by using life 
expectance of the general population and the 
mortality under the given treatment 
Life expectancy of expired 
patients (L_dead) 
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Table 2: Formulae for calculations of pay-offs for cost and effectiveness 
 
Pay-off Formula  
Cost  
Cost of treatment with albumin +crystalloids at 
survival (path1) 
Cost_std + cost_alb 
Cost of treatment with albumin +crystalloids at 
death (path2) 
Cost_std + cost_alb 
Cost of treatment with crystalloids at survival 
(path3) 
Cost_std 
Cost of treatment with crystalloids at death (path4) Cost_std 
Effectiveness   
Life expectancy with albumin+crystalloids 1/[(1/LEA) +(P_albu -1/LEA)] 
Life expectancy with crystalloids 1/[(1/LEA) +(P_cryst -1/LEA)] 
 
Table 3: Result summary table 
 
Summary measures Values  
Average cost Albumin+crystalloid $10857.7 
Crystalloid only $10362.7 
Life years gained Albumin+crystalloid 1.0 LYs 
Crystalloid only 0.91LYs 
Cost/life years gained Albumin+crystalloid 10,857.70 dollars/LY 





Cost ALCr-cost of albumin+crystalloid, CostCr- cost of crystalloid, life gained ALCr-life years gained by 
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Table 4: Results of one-way sensitivity analysis  
 
Variables  ICER  (low) ICER (high) ICER (low) ICER (high) 
 Probability of 
mortality with the 
addition albumin 




CE  Not CE  
Crystalloids   Not CE CE 
Probability 
mortality with 
standard care only 




Dominated CE  
Crystalloids  Dominant Not CE  




CE Not CE 
Crystalloids  Not CE CE 
Cost of standard 
care  




Not CE Not CE 
Crystalloids  CE CE 
Life expectancy 
with albumin 




Not CE  CE 
Crystalloids  CE Not CE 
Life expectancy 
with crystalloids 





Crystalloids  Not CE Dominant 
 




The results of our decision analysis indicate that 
albumin was not cost-effective relative to 
crystalloids in one GDP per capita for a life year 
gained. The total cost per life year for albumin 
($10,858) was lower than that of crystalloids 
($11,388).  Sensitivity analysis showed that this 
result was robust over a range of standard care cost. 
However, the result was sensitive to the cost of 
albumin, mortality rates and associated life year 
gains.  A similar study from the US revealed the 
cost-effectiveness of albumin-based resuscitation in 
severe sepsis and septic shock (13). The differences 
in the economic status and healthcare capacities 
might have contributed to the cost-effectiveness in 
US. 
          Our study was based on two fundamental 
assumptions. First, crystalloids and albumin were 
deemed to have no significant differences in terms 
of treatment-related adverse events. The crystalloids 
can be classified as physiologically balanced and 
isotonic saline (7). Isotonic saline differs from 
balanced crystalloids in two aspects (20). First, it 
does not contain a buffer. Second, it has a higher 
chloride concentration. These peculiar 
characteristics lead to the important adverse effect 
of isotonic saline, hyperchloremic metabolic 
acidosis and acute kidney injury. However, high-
chloride fluids use did not affect mortality (19,21). 
The second assumption is that albumin and 
crystalloids preparations show biopharmaceutical 
equivalence in each product class. 
          Recent studies on the volume of fluid for 
resuscitation, generally, discourage large volume 
resuscitation and positive fluid balance in severe 
sepsis and septic shock (22-24). A total volume of 
albumin equivalent to a third of the total volume of 
crystalloids is enough for a similar level of 
resuscitation (7). This may give albumin a privilege 
to reduce fluid overload.  Albumin’s additional 
properties like binding to nitric oxide, protection 
against lipid peroxidation and regulatory effects on 
inflammation might provide albumin a modulatory 
effect on sepsis pathogenesis (1). However, the 
main factor for fluid leakage and end-organ failure 
in sepsis is the damage on the endothelial 
glycocalyx (25,26). As a result, fluid therapy does 
not follow the usual Starling’s principle. This makes 
fluid resuscitation in sepsis complex. A number of 
studies concluded that albumin has no additional 
mortality benefit over crystalloids for patients with 
severe sepsis and septic shock (27-29).  
            The strengthes this study includes the use of 
patients from one of the few hospitals that have a 
well-equipped intensive care unit. This will serve to 
rule out other factors that might have contributed to 
the overall mortality. The cost of standard care, the 
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price of medications and the exchange rate were 
taken from the hospital and national databases 
without any estimation to avoid bias. Both 
deterministic and probabilistic sensitivity analyses 
were done. This study has a few limitations. First, 
the extraction of probabilities from a meta-analysis 
might introduce some bias. Second, the cut-off point 
employed for cost-effectiveness was chosen 
arbitrarily. Third, the practice variation among 
hospitals might decrease the generalizability the 
result extracted from a single center for the whole 
country. Last but not least, the volume of albumin 
was determined from dispensary database which 
might not necessarily indicate the volume 
administered to patients.  
          We cautiously conclude that the use of 
albumin for resuscitation of patients with severe 
sepsis and septic shock is not cost-effective at a 
GDP per capita for a life year gain in IRI. The cost-
effectiveness was insensitive to the cost of standard 
care. We strongly advise policy-makers and hospital 
administrators to consider this economic evaluation 
during the design of resuscitation protocols. 
However, to clearly show both the effectiveness and 
cost of albumin-based resuscitation, we recommend 
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